BMJ29 天
OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ...
1 Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen-Nürnberg and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany 2 Deutsches Zentrum ...
Frontiers1 个月
CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next ...
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, B-cell acute lymphoblastic ...
Frontiers1 个月
Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 ...
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, ...
Nature8 年
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...